Piper Sandler analyst Arvind Ramnani downgrades Accenture (NYSE:ACN) from Neutral to Underweight.
Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $17
Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target from $20 to $17.